Editors Choice Article | New Folate-Modified Human Serum Albumin Conjugated to Cationic Lipid Carriers for Dual Targeting of Mitoxantrone against Breast Cancer

 

Author(s): Abbas A. Ridha,  Soheila Kashanian*, Abbas H. Azandaryani, Ronak Rafipour, Elahe Mahdavian.

 

 

Graphical Abstract:

 

 

Abstract:

Aims: In the present work, folic acid-modified human serum albumin conjugated to cationic solid lipid nanoparticles were synthesized as nanocarriers of mitoxantrone for the treatment of breast cancer.

Background: Dual-targeted drug delivery is a new drug dosing strategy that is frequently used to enhance the therapeutic efficacy of anticancer drugs.

Objective: Dual targeting of the cancer cells was achieved by dual tagging of human serum albumin and folic acid on the surface of the lipid nanoparticles.
Methods: The targeted drug-loaded nanocomplexes were synthesized and characterized using transmission electron microscopy along with photon-correlation and Fourier-transform infrared spectroscopic techniques. The anti-cancer activity of the nanocomplexes was screened against an in-vitro model of MCF-7 and MDA-MB-231 breast cancer cell lines to examine drug efficacy.
Results: The entrapment efficiency and drug loading values for mitoxantrone were calculated to be 97 and 8.84%, respectively. The data from the drug release studies for the system indicated the release profile did not significantly change within a pH range of 5.5-7.4. The hemolysis ratio of the hybrid carrier was less than 5% even at the upper doses of 3 mg/mL, demonstrating its safety for intravenous injection with limited hemolysis and a long blood circulation time.
Conclusion: The cell cytotoxicity results confirmed that the drug hybrid nanocomplex was more toxic to breast cancer cells compared with the free drug. Furthermore, the weakly cationic and small size particles prevented opsonin binding of nanocomplexes, improving blood circulation time and cancer tissue uptake. To read out more, please visit: http://www.eurekaselect.com/node/176690

Editors Choice Article | Lipid-based Vehicles for siRNA Delivery in Biomedical Field

Journal Name: Current Pharmaceutical Biotechnology

Author(s): Tianzhong Li, Linfeng Huang*, Mengsu Yang*.

 

Graphical Abstract:

 

Abstract:

Background: Genetic drugs have aroused much attention in the past twenty years. RNA interference (RNAi) offers novel insights into discovering potential gene functions and therapies targeting genetic diseases. Small interference RNA (siRNA), typically 21-23 nucleotides in length, can specifically degrade complementary mRNA. However, targeted delivery and controlled release of siRNA remain a great challenge.

Methods: Different types of lipid-based delivery vehicles have been synthesized, such as liposomes, lipidoids, micelles, lipoplexes and lipid nanoparticles. These carriers commonly have a core-shell structure. For active targeting, ligands may be conjugated to the surface of lipid particles.

Results: Lipid-based drug delivery vehicles can be utilized in anti-viral or anti-tumor therapies. They can also be used to tackle genetic diseases or discover novel druggable genes.
Conclusion: In this review, the structures of lipid-based vehicles and possible surface modifications are described, and applications of delivery vehicles in biomedical field are discussed. To read out more, please visit: http://www.eurekaselect.com/175085/article

Wishing you a very Happy Birthday | Dr. Davide Prosperi

Comic Sans MS Regular.jpg

 

Dr. Davide Prosperi

EDITOR-IN-CHIEF: Current Pharmaceutical Biotechnology

Department of Biotechnology and Bioscience
University of Milano-Bicocca
Milano
Italy

PODCAST: Therapeutic Potential Of Small Activating RNAs (saRNAs) In Human Cancers

PODCAST BY: SORAH YOON

FOR ARTICLE DETAILS, PLEASE VISIT: http://www.eurekaselect.com/162489

SUBSCRIBE OUR YOUTUBE CHANNELHTTPS://BIT.LY/1LR0CZY

Aims & Scope – Current Pharmaceutical Biotechnology

Aims & Scope

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include:

  • DNA/protein engineering and processing
  • Synthetic biotechnology
  • Omics (genomics, proteomics, metabolomics and systems biology)
  • Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
  • Drug delivery and targeting
  • Nanobiotechnology
  • Molecular pharmaceutics and molecular pharmacology
  • Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes)
  • Pharmacokinetics and pharmacodynamics
  • Applied Microbiology
  • Bioinformatics (computational biopharmaceutics and modeling)
  • Environmental biotechnology
  • Regenerative medicine (stem cells, tissue engineering and biomaterials)
  • Translational immunology (cell therapies, antibody engineering, xenotransplantation)
  • Industrial bioprocesses for drug production and development
  • Biosafety
  • Biotech ethics

Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.

Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

 

cpb-flyer

 

For more details, please visit: https://benthamscience.com/journals/current-pharmaceutical-biotechnology/aims-scope/#top

Most Accessed Articles – CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Journal Name: Current Pharmaceutical Biotechnology

Author(s): Miliotou N. Androulla, Papadopoulou C. Lefkothea*.

 

 

 

Graphical Abstract:

 

 

Abstract:

Background: Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to their limited effectiveness in accordance with the heterogeneity of cancer cells, there is a constant search for therapeutic approaches with improved outcome, such as immunotherapy that utilizes and enhances the normal capacity of the patient’s immune system.

Methods: Chimeric Antigen Receptor (CAR) T-cell therapy involves genetic modification of patient’s autologous T-cells to express a CAR specific for a tumor antigen, following by ex vivo cell expansion and re-infusion back to the patient. CARs are fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. This T-cell genetic modification may occur either via viral-based gene transfer methods or nonviral methods, such as DNA-based transposons, CRISPR/Cas9 technology or direct transfer of in vitro transcribed-mRNA by electroporation.

Results: Clinical trials have shown very promising results in end-stage patients with a full recovery of up to 92% in Acute Lymphocytic Leukemia. Despite such results in hematological cancers, the effective translation of CAR T-cell therapy to solid tumors and the corresponding clinical experience is limited due to therapeutic barriers, like CAR T-cell expansion, persistence, trafficking, and fate within tumors.

Conclusion: In this review, the basic design of CARs, the main genetic modification strategies, the safety matters as well as the initial clinical experience with CAR T-cells are described.

 

For more details, please visit: http://www.eurekaselect.com/161365

Open Access Articles – Glutamatergic Deficits in Schizophrenia – Biomarkers and Pharmacological Interventions within the Ketamine Model

Journal Name: Current Pharmaceutical Biotechnology

Author(s): Moritz Haaf, Gregor Leicht, Stjepan Curic, Christoph Mulert*.

 

 

 

Graphical Abstract:

 

 

Abstract:

Background: The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. NMDAR hypofunction can explain many schizophrenia symptoms directly due to excitatory-to-inhibitory (E/I) imbalance, but also dopaminergic dysfunction itself. However, so far no new drug targeting the NMDAR has been successfully approved. In the search for possible biomarkers it is interesting that ketamine-induced psychopathological changes in healthy participants were accompanied by altered electro-(EEG), magnetoencephalographic (MEG) and functional magnetic resonance imaging (fMRI) signals.

Methods: We systematically searched PubMed/Medline and Web of Knowledge databases (January 2006 to July 2017) to identify EEG/MEG and fMRI studies of the ketamine model of schizophrenia with human subjects. The search strategy identified 209 citations of which 46 articles met specified eligibility criteria.

Results: In EEG/MEG studies, ketamine induced changes of event-related potentials, such as the P300 potential and the mismatch negativity, similar to alterations observed in schizophrenia patients. In fMRI studies, alterations of activation were observed in different brain regions, most prominently within the anterior cingulate cortex and limbic structures as well as task-relevant brain regions. These alterations were accompanied by changes in functional connectivity, indicating a balance shift of the underlying brain networks. Pharmacological treatments did alter ketamine-induced changes in EEG/MEG and fMRI studies to different extents.

Conclusion: This review highlights the potential applicability of the ketamine model for schizophrenia drug development by offering the possibility to assess the effect of pharmacological agents on schizophrenia- like symptoms and to find relevant neurophysiological and neuroimaging biomarkers.

 

 

For more details, please visit: http://www.eurekaselect.com/163122

New Issue :: Current Pharmaceutical Biotechnology (Volume: 19, Issue: 6)

 

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology.

cpb.jpg

 

Articles from the journal Current Pharmaceutical Biotechnology Volume 19, Issue 6:

 

 

For details on the articles, please visit this link ::  https://bit.ly/2Qao2Xv

 

New Issue :: Current Pharmaceutical Biotechnology (Volume: 19, Issue: 3)

 

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology.

 

cpb.jpg

 

Articles from the journal Current Pharmaceutical Biotechnology Volume 19 Issue 3:

 

For details on the articles, please visit this link ::  https://bit.ly/2LxuTbK

New Issue :: Current Pharmaceutical Biotechnology (Volume: 19, Issue: 2)

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication.

 cpb.jpg

%d bloggers like this: